Laden…
Evidence-based risk assessment and known adverse effects
Risk Classification: Moderate Risk
2C-I carries a moderate risk profile. Acute and chronic risks depend significantly on dose, frequency, route of administration, and individual predispositions.
Neurotoxicity
none_known
The following substances carry an elevated risk of adverse interactions with 2C-I. This list is not exhaustive.
For a full interaction overview, see the Interactions page.
general
2C-I gilt als milder als 2C-E — trotzdem körperlich anspruchsvoll und mentale Vorbereitung wichtig
dosing
Oral: 10–20 mg für Erstanwender. Wirkungseintritt 60–90 Minuten
setting
Set & Setting: ruhige Umgebung, vertraute Personen — Visuals können intensiv sein
combinations
Kein Lithium, keine MAO-Hemmer
health
Stimulierende Komponente (Phenethylamin) beachten: Herzfrequenz und Blutdruck steigen
dosing
Toleranzentwicklung: mind. 1 Woche Pause nach jeder Erfahrung
Disclaimer: This information is provided for educational purposes only and does not constitute medical advice. If you have concerns about substance use, please consult a qualified healthcare professional or contact a local drug support service.